Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy.

Literature DB >> 402258

Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy.

R M Pinder, R N Brogden, T M Speight, G S Avery.

Abstract

Sodium valproate has a broad spectrum of anticonvulsant activity, but is structurally unrelated to conventional antiepileptic drugs. Its proposed mode of action is mediated through effects on the function of brain gamma-aminobutyric acid (GABA). However, the elevations in brain and cerebellar GABA, and the concomitant reductions in levels of cyclic guanosine monophosphate, occur in animals at dose levels which are unlikely to be achieved during treatment of epileptic patients.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1977 PMID： 402258 DOI： 10.2165/00003495-197713020-00001

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

78 in total

1. [Pharmacodynamic properties of N-dipropylacetic acid].

Authors: H MEUNIER; G CARRAZ; Y NEUNIER; P EYMARD; M AIMARD
Journal: Therapie Date: 1963 Mar-Apr Impact factor: 2.070

2. [Effects of n-dipropylacetic acid (Depakine) on the activity of the cortical epileptic focus produced with cobalt].

Authors: R Mutani; R Fariello
Journal: Riv Patol Nerv Ment Date: 1969-01

3. Controlled trial of sodium valproate in severe epilepsy.

Authors: A Richens; S Ahmad
Journal: Br Med J Date: 1975-11-01

4. The effects of n-dipropylacetate on the acquisition of conditioned behaviour with negative reinforcement in mice.

Authors: R Misslin; P Ropartz; P Mandel
Journal: Psychopharmacologia Date: 1975-11-21

5. The treatment of childhood epilepsy with sodium valproate.

Authors: D Haigh; W I Forsythe
Journal: Dev Med Child Neurol Date: 1975-12 Impact factor: 5.449

6. Sodium valproate and thrombocytopenia.

Authors: D A Winfield; P Benton; M L Espir; L J Arthur
Journal: Br Med J Date: 1976-10-23

7. [Results obtained with Depakine in epilepsy resistant to other therapies. Preliminary note].

Authors: M Dumon-Radermecker
Journal: Acta Neurol Psychiatr Belg Date: 1969-11

8. Anticonvulsant action of ethanolamine-O-sulphate and di-n-propylacetate and the metabolism of gamma-aminobutyric acid (GABA) in mice with audiogenic seizures.

Authors: G Anlezark; R W Horton; B S Meldrium; C B Sawaya
Journal: Biochem Pharmacol Date: 1976-02-15 Impact factor: 5.858

9. Sodium valproate in the treatment of resistant epilepsy.

Authors: M N Hassan; H C Laljee; M J Parsonage
Journal: Acta Neurol Scand Date: 1976-09 Impact factor: 3.209

10. [Preliminary clinical electroencephalographic study on the treatment of epilepsy with sodium dipropylacetate (Depakine)].

Authors: R Balbi; F Bravaccio
Journal: Acta Neurol (Napoli) Date: 1972 Sep-Oct

48 in total

1. Neurology-epitomes of progress: valproate: newest anticonvulsant.

Authors: R I Pfeffer
Journal: West J Med Date: 1980-02

Review 2. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.

Authors: Sarah J Nevitt; Maria Sudell; Jennifer Weston; Catrin Tudur Smith; Anthony G Marson
Journal: Cochrane Database Syst Rev Date: 2017-06-29

3. Anaesthesia abolishes the effect of valproate on extracellular 5-HIAA, DOPAC and ascorbate as measured in rat striatum by differential pulse voltammetry.

Authors: F Crespi; P E Keane; M Morre
Journal: Br J Pharmacol Date: 1986-01 Impact factor: 8.739

Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy.

1. [Pharmacodynamic properties of N-dipropylacetic acid].

2. [Effects of n-dipropylacetic acid (Depakine) on the activity of the cortical epileptic focus produced with cobalt].

3. Controlled trial of sodium valproate in severe epilepsy.

4. The effects of n-dipropylacetate on the acquisition of conditioned behaviour with negative reinforcement in mice.

5. The treatment of childhood epilepsy with sodium valproate.

6. Sodium valproate and thrombocytopenia.

7. [Results obtained with Depakine in epilepsy resistant to other therapies. Preliminary note].

8. Anticonvulsant action of ethanolamine-O-sulphate and di-n-propylacetate and the metabolism of gamma-aminobutyric acid (GABA) in mice with audiogenic seizures.

9. Sodium valproate in the treatment of resistant epilepsy.

10. [Preliminary clinical electroencephalographic study on the treatment of epilepsy with sodium dipropylacetate (Depakine)].

1. Neurology-epitomes of progress: valproate: newest anticonvulsant.

Review 2. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.

3. Anaesthesia abolishes the effect of valproate on extracellular 5-HIAA, DOPAC and ascorbate as measured in rat striatum by differential pulse voltammetry.

Review 4. Disposition of anticonvulsants in childhood.

5. Single and chronic dose pharmacokinetic studies of sodium valproate in epileptic patients.

6. Disposition of valproic acid in patients with liver disease.

7. Recent advances in drug therapy for epilepsy.

8. Effect of sodium valproate on motor function regulated by the activation of GABA receptors.

9. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero.

10. Inhibition of ureagenesis by valproate in rat hepatocytes. Role of N-acetylglutamate and acetyl-CoA.